Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection

NCT04452565 is registered in ClinicalTrials.gov with Biomed Industries, Inc. as lead sponsor.

NCT NCT04452565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04452565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection
Lead sponsor
Biomed Industries, Inc.
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 15, 2022
Completion date
December 15, 2023
Enrollment
525 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infection, severe acute respiratory infection, severe acute respiratory syndrome coronavirus 2